Kymera Therapeutics KYMR
NASDAQ KYMR
$117.45 +0.17 (+0.14%)
As of: Sep 4, 2026 · 3:59 PM EDT

Kymera Therapeutics (KYMR) EV to CFO (2020 - 2026)

Analysis

Kymera Therapeutics (KYMR) EV to CFO (2020 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Kymera Therapeutics 11.52 Bn 10.83 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -162.81
Mar 31, 2026 -69.72
Dec 31, 2025 -82.09
Sep 30, 2025 -131.13
Jun 30, 2025 -40.31
Mar 31, 2025 -16.66
Dec 31, 2024 -34.34
Sep 30, 2024 -50.10
Jun 30, 2024 -30.93
Mar 31, 2024 -49.15
Dec 31, 2023 129.31
Sep 30, 2023 -13.05
Jun 30, 2023 -25.69
Mar 31, 2023 -28.22
Dec 31, 2022 -24.45
Sep 30, 2022 -20.72
Jun 30, 2022 -16.12
Mar 31, 2022 -43.85
Dec 31, 2021 -73.78
Sep 30, 2021 -66.41